TY - JOUR
T1 - Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada
AU - Solomon, Jacqueline M.
AU - Jones, Ashley
AU - Hohol, Marika
AU - Krysko, Kristen M.
AU - Muccilli, Alexandra
AU - Roll, Alexandra
AU - Rotstein, Dalia
AU - Schneider, Raphael
AU - Selchen, Daniel
AU - Vosoughi, Reza
AU - Baral, Stefan D.
AU - Oh, Jiwon
N1 - Funding Information:
J.O. reports grants from MS Society of Canada, Barford and Love MS Fund of St. Michael's Hospital Foundation, National MS Society, Brain Canada, Biogen-Idec, Roche, and EMD-Serono; and personal fees for consulting or speaking from Biogen-Idec, EMD-Serono, Roche, Sanofi-Genzyme, Novartis, and BMS.
Funding Information:
J.M.S.’s fellowship was supported by the St. Michael's Hospital Foundation's Beth Malcom Fellowship
Funding Information:
D.R. has received research support from the MS Society of Canada, CMSC, and Roche Canada. She has acted as a speaker or consultant for Alexion, Biogen, EMD Serono, Novartis, Roche, and Sanofi Aventis.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/2
Y1 - 2022/2
N2 - Objective: To report clinical characteristics and outcomes of people with multiple sclerosis (PwMS) who developed COVID-19 infection in Toronto, Canada. Methods: Descriptive, retrospective, single-center study that included all known PwMS at the St. Michael's Hospital MS Clinic who had PCR-confirmed COVID-19 infection between March 2020 and May 2021. Results: Of 7000 PwMS in our clinic, 80 (1.1%) tested positive for SARS-CoV-2. Fifty-four (67.5%) were on disease-modifying therapy (DMT) without over-representation of any single treatment. Seventy-one patients (88.8%) had mild symptoms, but nine (11.3%) were hospitalized and one 70-year-old male patient not on treatment died. Of those hospitalized, one-third were treated with ocrelizumab. Conclusion: In Toronto, PwMS did not appear to have higher prevalence of COVID-19 infection compared to the general population, but disease severity may be affected by DMT use. Our findings add to the accumulating global data regarding COVID-19 infection in PwMS.
AB - Objective: To report clinical characteristics and outcomes of people with multiple sclerosis (PwMS) who developed COVID-19 infection in Toronto, Canada. Methods: Descriptive, retrospective, single-center study that included all known PwMS at the St. Michael's Hospital MS Clinic who had PCR-confirmed COVID-19 infection between March 2020 and May 2021. Results: Of 7000 PwMS in our clinic, 80 (1.1%) tested positive for SARS-CoV-2. Fifty-four (67.5%) were on disease-modifying therapy (DMT) without over-representation of any single treatment. Seventy-one patients (88.8%) had mild symptoms, but nine (11.3%) were hospitalized and one 70-year-old male patient not on treatment died. Of those hospitalized, one-third were treated with ocrelizumab. Conclusion: In Toronto, PwMS did not appear to have higher prevalence of COVID-19 infection compared to the general population, but disease severity may be affected by DMT use. Our findings add to the accumulating global data regarding COVID-19 infection in PwMS.
KW - COVID-19
KW - Disease-modifying therapy
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85122595679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122595679&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2022.103509
DO - 10.1016/j.msard.2022.103509
M3 - Letter
C2 - 35030366
AN - SCOPUS:85122595679
SN - 2211-0348
VL - 58
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 103509
ER -